BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 15014037)

  • 1. VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.
    Minderman H; O'Loughlin KL; Pendyala L; Baer MR
    Clin Cancer Res; 2004 Mar; 10(5):1826-34. PubMed ID: 15014037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023.
    Minderman H; Brooks TA; O'Loughlin KL; Ojima I; Bernacki RJ; Baer MR
    Cancer Chemother Pharmacol; 2004 May; 53(5):363-9. PubMed ID: 15060738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporin A is a broad-spectrum multidrug resistance modulator.
    Qadir M; O'Loughlin KL; Fricke SM; Williamson NA; Greco WR; Minderman H; Baer MR
    Clin Cancer Res; 2005 Mar; 11(6):2320-6. PubMed ID: 15788683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells.
    Brooks TA; O'Loughlin KL; Minderman H; Bundy BN; Ford LA; Vredenburg MR; Bernacki RJ; Priebe W; Baer MR
    Invest New Drugs; 2007 Apr; 25(2):115-22. PubMed ID: 17072745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties.
    Jekerle V; Klinkhammer W; Reilly RM; Piquette-Miller M; Wiese M
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):61-9. PubMed ID: 16636798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP.
    Germann UA; Ford PJ; Shlyakhter D; Mason VS; Harding MW
    Anticancer Drugs; 1997 Feb; 8(2):141-55. PubMed ID: 9073310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.
    Jekerle V; Klinkhammer W; Scollard DA; Breitbach K; Reilly RM; Piquette-Miller M; Wiese M
    Int J Cancer; 2006 Jul; 119(2):414-22. PubMed ID: 16646006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.
    Brooks TA; Minderman H; O'Loughlin KL; Pera P; Ojima I; Baer MR; Bernacki RJ
    Mol Cancer Ther; 2003 Nov; 2(11):1195-205. PubMed ID: 14617793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BIRICODAR (VX-710; Incel): an effective chemosensitizer in neuroblastoma.
    Yanagisawa T; Newman A; Coley H; Renshaw J; Pinkerton CR; Pritchard-Jones K
    Br J Cancer; 1999 Jun; 80(8):1190-6. PubMed ID: 10376971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
    Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
    Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity analysis of taxane-based broad-spectrum multidrug resistance modulators.
    Brooks TA; Kennedy DR; Gruol DJ; Ojima I; Baer MR; Bernacki RJ
    Anticancer Res; 2004; 24(2A):409-15. PubMed ID: 15152938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2).
    Litman T; Brangi M; Hudson E; Fetsch P; Abati A; Ross DD; Miyake K; Resau JH; Bates SE
    J Cell Sci; 2000 Jun; 113 ( Pt 11)():2011-21. PubMed ID: 10806112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies.
    Zhou XF; Yang X; Wang Q; Coburn RA; Morris ME
    Drug Metab Dispos; 2005 Aug; 33(8):1220-8. PubMed ID: 15908473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
    Robey RW; Medina-PĂ©rez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
    Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979.
    Shepard RL; Cao J; Starling JJ; Dantzig AH
    Int J Cancer; 2003 Jan; 103(1):121-5. PubMed ID: 12455064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of H+-ATPase-dependent activity of multidrug resistance-associated protein in homoharringtonine-resistant human leukemic K562 cells.
    Benderra Z; Morjani H; Trussardi A; Manfait M
    Leukemia; 1998 Oct; 12(10):1539-44. PubMed ID: 9766497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants.
    Miwa M; Tsukahara S; Ishikawa E; Asada S; Imai Y; Sugimoto Y
    Int J Cancer; 2003 Dec; 107(5):757-63. PubMed ID: 14566825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of daunorubicin cellular resistance by combination of P-glycoprotein blockers acting on drug efflux and intracellular drug sequestration in Golgi vesicles.
    Merlin JL; Bour-Dill C; Marchal S; Ramacci C; Poullain MG; Giroux B
    Cytometry; 2000 Sep; 41(1):62-72. PubMed ID: 10942898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
    Jonker JW; Smit JW; Brinkhuis RF; Maliepaard M; Beijnen JH; Schellens JH; Schinkel AH
    J Natl Cancer Inst; 2000 Oct; 92(20):1651-6. PubMed ID: 11036110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells.
    Yang CH; Schneider E; Kuo ML; Volk EL; Rocchi E; Chen YC
    Biochem Pharmacol; 2000 Sep; 60(6):831-7. PubMed ID: 10930538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.